Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Author:

O’Reilly Eileen M.1,Oh Do-Youn2,Dhani Neesha3,Renouf Daniel J.4,Lee Myung Ah5,Sun Weijing6,Fisher George7,Hezel Aram8,Chang Shao-Chun9,Vlahovic Gordana9,Takahashi Osamu9,Yang Yin9,Fitts David10,Philip Philip Agop11

Affiliation:

1. Gastrointestinal Medical Oncology, David M. Rubenstein Center for Pancreatic Cancer, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York

2. Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea

3. Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

4. Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada

5. Department of Oncology, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea

6. Division of Medical Oncology, University of Kansas Medical Center, Kansas City

7. Department of Medicine–Medical Oncology, Stanford University, Stanford, California

8. Division of Hematology and Oncology, University of Rochester, Rochester, New York

9. AstraZeneca, Gaithersburg, Maryland

10. Independent Biostatistician, Durham, North Carolina

11. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Reference45 articles.

1. Pancreatic cancer genetics.;Amundadottir;Int J Biol Sci,2016

2. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies.;Chiaravalli;Cancer Treat Rev,2017

3. Addressing the challenges of pancreatic cancer: future directions for improving outcomes.;Hidalgo;Pancreatology,2015

4. Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA).;Uccello;Curr Oncol,2018

5. Pancreatic ductal adenocarcinoma: from genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.;Fokas;Biochim Biophys Acta,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3